Published 2022
| Version v1
Publication
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study
Creators
- De Laurentiis, Michelino
- Caputo, Roberta
- Mazza, Manuelita
- Mansutti, Mauro
- Masetti, Riccardo
- Ballatore, Zelmira
- Torrisi, Rosalba
- Michelotti, Andrea
- Zambelli, Alberto
- Ferro, Antonella
- Generali, Daniele
- Vici, Patrizia
- Coltelli, Luigi
- Fabi, Alessandra
- Marchetti, Paolo
- Ballestrero, Alberto
- Spazzapan, Simon
- Frassoldati, Antonio
- Sarobba, Maria Giuseppina
- Grasso, Donatella
- Zamagni, Claudio
Contributors
Others:
- De Laurentiis, Michelino
- Caputo, Roberta
- Mazza, Manuelita
- Mansutti, Mauro
- Masetti, Riccardo
- Ballatore, Zelmira
- Torrisi, Rosalba
- Michelotti, Andrea
- Zambelli, Alberto
- Ferro, Antonella
- Generali, Daniele
- Vici, Patrizia
- Coltelli, Luigi
- Fabi, Alessandra
- Marchetti, Paolo
- Ballestrero, Alberto
- Spazzapan, Simon
- Frassoldati, Antonio
- Sarobba, Maria Giuseppina
- Grasso, Donatella
- Zamagni, Claudio
Description
Ribociclib plus letrozole demonstrated manageable safety and efficacy profiles in hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) in the Phase 3b CompLEEment-1 trial.
Additional details
Identifiers
- URL
- https://hdl.handle.net/11567/1100554
- URN
- urn:oai:iris.unige.it:11567/1100554
Origin repository
- Origin repository
- UNIGE